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ABSTRACT
Objectives To estimate, overall and by organism, the
incidence of infectious intestinal disease (IID) in the
community, presenting to general practice (GP) and
reported to national surveillance.
Design Prospective, community cohort study and
prospective study of GP presentation conducted
between April 2008 and August 2009.
Setting Eighty-eight GPs across the UK recruited from
the Medical Research Council General Practice Research
Framework and the Primary Care Research Networks.
Participants 6836 participants registered with the 88
participating practices in the community study; 991
patients with UK-acquired IID presenting to one of 37
practices taking part in the GP presentation study.
Main outcome measures IID rates in the community,
presenting to GP and reported to national surveillance,
overall and by organism; annual IID cases and GP
consultations by organism.
Results The overall rate of IID in the community was
274 cases per 1000 person-years (95% CI 254 to 296);
the rate of GP consultations was 17.7 per 1000 person-
years (95% CI 14.4 to 21.8). There were 147 community
cases and 10 GP consultations for every case reported to
national surveillance. Norovirus was the most common
organism, with incidence rates of 47 community cases
per 1000 person-years and 2.1 GP consultations per
1000 person-years. Campylobacter was the most
common bacterial pathogen, with a rate of 9.3 cases per
1000 person-years in the community, and 1.3 GP
consultations per 1000 person-years. We estimate that
there are up to 17 million sporadic, community cases of
IID and 1 million GP consultations annually in the UK.
Of these, norovirus accounts for 3 million cases and
130000 GP consultations, and Campylobacter is
responsible for 500000 cases and 80000 GP
consultations.
Conclusions IID poses a substantial community and
healthcare burden in the UK. Control efforts must focus
particularly on reducing the burden due to Campylobacter
and enteric viruses.
BACKGROUND
The Health Protection Agency recorded 49880
laboratory-conﬁrmed cases of infectious intestinal
disease (IID) due to Campylobacter and 9885 cases of
non-typhoidal salmonellosis in England and Wales
in 2008
1 2; rotavirus and norovirus accounted for
13935 and 6828 reports, respectively.
34Most IID is
self-limiting, requiring no clinical intervention, but
commonly causes high levels of healthcare usage
and absenteeism.
5 Organisms such as verocyto-
toxin-producing Escherichia coli (VTEC) and
Campylobacter are also associated with long-term,
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Signiﬁcance of this study
What is already known about this subject?
< Infectious intestinal disease (IID) is a common
cause of illness in the community and results in
a high burden of consultations to general
practice (GP).
< Most cases of IID are not reported to national
surveillance systems, making it difﬁcult to
determine the true burden in the population.
< Recent interventions and changes in healthcare
delivery may have resulted in changes in
disease burden in the community and presenting
to primary care; population-based studies are
needed to monitor such changes.
What are the new ﬁndings?
< In the UK, there are up to 17 million cases and 1
million GP consultations due to IID every year.
< Although IID incidence in the community
appears to have increased since the 1990s,
consultations to GP have halved.
< Norovirus is the most common recognised
cause of IID, accounting for 3 million cases
and 130000 GP consultations annually, while
Clostridium difﬁcile, an important pathogen in
healthcare settings, is a rare cause of diarrhoea
in the community.
How might it impact on clinical practice in the
foreseeable future?
< Use of recently introduced telephone advice
services such as NHS Direct is relatively low
and has little impact on the burden of GP
consultations for IID. Instead, changes in health-
care use are likely to be behind the decreasing
trend in IID-related GP consultations.
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Intestinal infectionspotentially fatal sequelae, including haemolytic uraemic
syndrome
6 and GuillaineBarré syndrome.
7
National statistics underestimate the incidence, because only
a fraction of IID presents to health services, and many
presenting cases are not investigated further. Reported cases are
not a random subset of all cases, as seeking healthcare is related
to greater disease severity, recent foreign travel and lower
socioeconomic status.
8 National statistics can be useful for
monitoring trends, but difﬁcult to interpret if there are secular
changes in healthcare-seeking behaviour, faecal sampling,
diagnostic procedures or surveillance methods. Evaluating
control strategies requires accurately estimating population
burden and understanding the relationship between national
statistics and disease incidence.
In its ﬁrst 5 years of operation the UK, Food Standards Agency
was tasked with reducing food-borne illness by 20%.
9 The
Second Study of IID in the UK (IID2 Study) was commissioned
to assess progress towards this target and determine whether
changes in healthcare provision might inﬂuence the
interpretation of national statistics.
We present results from the IID2 Study, a multicentre longi-
tudinal study to estimate the current incidence of IID in the
community, presenting to general practice (GP) and reported to
national surveillance.
METHODS
The IID2 Study methods are detailed elsewhere.
10 Brieﬂy, we
conducted the study between 28 April 2008 and 31 August 2009
in a population of 800000 people served by 88 UK GPs. We
recruited practices from the Medical Research Council General
Practice Research Framework and Primary Care Research
Networks in England, Northern Ireland and Scotland. The
number of practices in the four UK countries was proportional
to population size. The study comprised a population cohort,
a GP presentation study and a national surveillance study.
Population cohort study
We followed up participants from 88 practices weekly for
symptoms of diarrhoea and/or vomiting for up to 52 weeks,
recruiting throughout the study period. From each practice list,
we invited randomly selected individuals to a recruitment
interview with the practice study nurse. People were eligible if
they did not have: a terminal illness or severe mental incapacity;
a recognised, non-infectious cause of diarrhoea or vomiting
(precluding determination of onset date and infectious
aetiology), such as Crohn’s disease, ulcerative colitis, cystic
ﬁbrosis or coeliac disease; or a surgical obstruction. Non-English
speakers were also excluded.
We asked participants to report weekly, by email or prepaid
postcard, whether or not they had experienced diarrhoea and/or
vomiting. We asked those reporting symptoms to complete
a case questionnaire, enquiring about type and duration of
symptoms, healthcare usage and recent travel, and to submit
a stool specimen for microbiological examination. We asked
them not to report symptoms related to excess alcohol, morning
sickness or, among infants, regurgitation.
GP presentation study
In 37 of the 88 participating practices, we asked GPs to refer to
the study nurse all patients presenting with IID. The nurse
administered a case questionnaire and requested a stool
specimen. To assess the degree of under-ascertainment of IID
cases in this study (ie, the proportion of all IID cases actually
referred and recruited to the study), study nurses searched the
computerised practice records monthly, using a predeﬁned list of
diagnostic Read codes,
11 to identify all IID-related consultations.
National surveillance study
We obtained records of IID cases reported in each UK country
over the study period, by organism, from the UK national
surveillance centres. Data on sapovirus and non-O157 VTEC
were not available, because they are not routinely reported. We
excluded national C difﬁcile reports because these are mostly
from healthcare settings rather than the community.
NHS direct usage
We obtained the number of telephone consultations to NHS
Direct (England only) for diarrhoea and vomiting during the
study period from the Health Protection Agency Birmingham
Regional Surveillance Unit.
Ethics approval
All participants gave signed, informed consent. The North West
Research Ethics Committee granted a favourable ethics opinion
(07/MRE08/5), and 37 NHS Research Management and Gover-
nance organisations for the 88 practices approved the study.
Case deﬁnitions
Deﬁnite IID was deﬁned as loose stools or clinically signiﬁcant
vomiting lasting less than 2 weeks, in the absence of a known
non-infectious cause, preceded by a symptom-free period of
3 weeks. Vomiting was clinically signiﬁcant if it occurred more
than once in a 24 h period and if it incapacitated the patient or
was accompanied by other symptoms such as cramps or
fever.
10 12 Symptomatic people not meeting the case deﬁnition
because they did not provide a questionnaire or because
symptom information was missing were considered possible
IID cases. Cases in which the patient reported travel outside
the UK in the 10 days before illness onset were excluded.
Microbiological analysis
First, all stool samples were cultured for Campylobacter jejuni/coli,
E coli O157, Listeria monocytogenes, Salmonella spp., Shigella spp.
and Yersinia spp. They were also examined by ELISA for Clos-
tridium perfringens enterotoxin, C difﬁcile cytotoxins A and B,
Cryptosporidium and Giardia, by a commercial PCR test
(Cepheid) for C difﬁcile, and by light microscopic examination of
a stained smear for Cyclospora and Cryptosporidium. Samples that
were immunoassay positive for C difﬁcile toxin or PCR-positive
were cultured using National Standard Method BSOP 10, and all
isolates were ribotyped.
13 Samples from children under 5 years
were examined for rotavirus and adenovirus 40/41 by
immunoassay.
Next, two nucleic acid extracts were prepared from each stool
sample.
14e16 Each extract was examined by real-time PCR for C
jejuni, C coli, L monocytogenes, Salmonella spp., rotavirus, noro-
virus, sapovirus, adenovirus, astrovirus, Cryptosporidium, Giardia
and E coli (enteroaggregative and VTEC (genes encoding VT1
and VT2)).
Further information on microbiological methods has been
published elsewhere.
10 For quantitative PCR assays, a cycle
threshold value <40 was considered positive for most organisms,
with two exceptions: a cycle threshold cut-off value <30 was
used to deﬁne clinically signiﬁcant norovirus and rotavirus
infection.
17 18
In this study, C difﬁcile-associated diarrhoea (CDAD) was
deﬁned as symptoms of diarrhoea not attributable to another
70 Gut 2012;61:69e77. doi:10.1136/gut.2011.238386
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a positive C difﬁcile toxin assay, in a patient aged >2 years.
19
Data analysis
We calculated incidence rates of IID with 95% CIs, overall and
by organism. In the cohort study, the denominator was the total
person-years at risk among cohort participants. Individuals
could contribute multiple episodes of illness. We omitted the
ﬁrst 3 weeks of follow-up to exclude prevalent cases. Participants
were followed-up until the 52nd week, or 31 August 2009, or
until they dropped out or withdrew for other reasons, whichever
occurred earliest. People were ‘dropped out’ after four consecu-
tive non-response weeks.
In the GP presentation study, the denominator in each prac-
tice was the practice population on 31 December 2008
multiplied by the time the practice was in the study. For the
national surveillance component, the denominator was the UK
midyear population at the 2001 census. For the NHS Direct
component, the mid-2001 England population was used.
Statistical adjustments
We standardised rates in the cohort study to the UK census age
and sex population structure. We adjusted rates in the GP
presentation study by an under-ascertainment factor repre-
senting the ratio of all cases identiﬁed in the practice records to
actual cases recruited. We obtained the under-ascertainment
factors from a two-level logistic regression model using age
group, sex, Read code category, and a random intercept for GP
practice to predict the probability of a case being recruited. We
grouped the Read codes assigned to each consultation into seven
categories: diarrhoea; vomiting; diarrhoea and vomiting;
gastroenteritis; organism-speciﬁc codes; codes indicating that
a stool sample was sent for analysis; and codes for symptoms
compatible with IID, for example, ‘gastrointestinal symptoms’.
We used the inverse of the predicted ascertainment probabilities
obtained from the model as under-ascertainment factors in the
incidence calculations.
CIs accounted for clustering of observations within individ-
uals (cohort study) and within practices (GP presentation
study).
Imputation of specimen data
We used multiple imputation by chained equations
20 to account
for missing organism data in participants who did not submit
a specimen. We developed separate imputation models for cases
in the cohort and GP presentation studies. For each organism,
the imputation model included age group, sex and presence or
absence of ﬁve symptoms (diarrhoea, bloody diarrhoea,
vomiting, abdominal pain and fever) as covariates. Overall, we
imputed values for 35% of records in the cohort study and 11%
of records in the GP presentation study. We combined results
from analysis of 20 imputed datasets to produce a point
estimate for the rate and 95% CI, accounting for uncertainty in
the observed rate and the imputation process.
Reporting ratios
We calculated rate ratios comparing rates in the community,
presenting to the GP and reported to national surveillance. We
assumed that the rates came from a log-normal distribution
with the observed mean and SD. The rate ratios were estimated
by simulating 100000 random draws from each pair of rate
distributions. We took the median, 2.5th and 97.5th centiles of
the resulting RR distribution as the point estimate and lower
and upper 95% conﬁdence limits.
Finally, we applied the estimated rates to the mid-2009 UK
population estimate to calculate the annual number of cases and
GP consultations associated with each organism.
Multiple imputation was conducted in R 2.11. Analysis of
under-ascertainment and analysis of imputed data were
performed using the glamm
21 and mi
22 modules in Stata V.11,
respectively.
Figure 1 Recruitment in the cohort
study, Infectious Intestinal Disease 2
Study, UK 2008e9.
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Participation
Of 77995 people invited in the cohort study, 8336 (10.5%)
responded positively and 7033 were recruited (9.0%) (ﬁgure 1).
Some people recruited near the study end date had no eligible
follow-up time (n¼184), and two people withdrew consent. We
analysed data from 6836 participants. Compared with the 2001
census population, cohort participants were more likely to be
older, female, employed in managerial and professional occupa-
tions, less deprived and in rural areas (online appendix 1). The
median follow-up duration was 39 weeks (IQR 27e45 weeks);
overall, 86% of the maximum achievable follow-up time to 31
August 2009 was completed. Six hundred and ten (9.5%)
participants dropped out, accounting for 219 (4.5%) lost person-
years of follow-up.
In the GP presentation study, 2233 eligible symptomatic
patients were referred and 2203 invited to participate. A total of
1392 people (63.2%) responded positively, and 1254 (56.9%)
were recruited (ﬁgure 2). We excluded 140 people reporting
recent foreign travel, 77 with illness lasting over 2 weeks, and 46
because of missing or inconsistent information on symptoms
and/or travel. Ultimately, we analysed data from 991 cases.
Rate of overall IID
There were 4658 person-years of follow-up and 1201 deﬁnite IID
cases in the cohort. The crude IID incidence rate was 258 cases
per 1000 person-years. The age- and sex-standardised rate was
274 cases per 1000 person-years (95% CI 254 to 296). When both
deﬁnite and possible cases were considered, this rose to 523 cases
per 1000 person-years (95% CI 497 to 551). There was little
evidence that rates varied by socioeconomic characteristics or
between urban and rural areas (data not shown).
In the under-ascertainment analysis, approximately one case
was recruited into the GP presentation study for every six
identiﬁed in the medical records, although this varied by age
group, Read code category and practice. After adjustment for
under-ascertainment, there were 5546 IID cases and 312232
person-years of follow-up, yielding a consultation rate of 17.7
per 1000 person-years (95% CI 14.4 to 21.8). This was lower
than that estimated from deﬁnite cases in the cohort who
reported consulting their GP for their illness (25.3 cases per 1000
person-years, 95% CI 20.7 to 31.3). The age-speciﬁc rates of GP
consultation in the two studies were similar except for young
children and older adults (ﬁgure 3). Among children <5 years,
the rate was 133 consultations per 1000 person-years in the
cohort study (95% CI 92 to 199) and 85 consultations per 1000
person-years in the GP presentation study (95% CI 59 to 122),
while among those aged 65 and over, the corresponding rates
were 30 consultations per 1000 person-years (95% CI 22 to 42)
and 20 consultations per 1000 person-years (95% CI 15 to 27),
respectively.
Call rates to NHS Direct in England for diarrhoea and
vomiting were 6.1 per 1000 person-years, similar to that esti-
mated from cohort study patients in England who reported
contacting NHS Direct for their illness (5.5 per 1000 person-
years, 95% CI 3.4 to 9.5).
Rates of IID by organism
Rates of IID by organism in the community, presenting to the
GP and reported to national surveillance are shown in table 1.
For organisms tested by more than one method, rate estimates
are presented separately for routine diagnostic methods and for
routine and PCR methods combined.
Rates in the community
Viruses predominated among IID cases in the community: the
estimated rates (cases per 1000 person-years) were 47 for noro-
virus, 26 for sapovirus, 13 for rotavirus and 10 for adenovirus.
The most common bacteria were Campylobacter (11 cases per
1000 person-years) and enteroaggregative E coli (six cases per
1000 person-years). The Salmonella rate was less than one case
per 1000 person-years. Based on ELISA, Cryptosporidium and
Giardia rates were around one case per 1000 person-years,
although PCR-based estimates were slightly higher.
E coli O157 was present in only one sample, and there were no
cases of CDAD or L monocytogenes IID in the community cohort.
GP presentation rates
Norovirus was the most common organism among cases
presenting to the GP (two consultations per 1000 person-years
(table 1)); approximately one in every 23 people with norovirus
IID consulted a GP. Rotavirus and sapovirus were also common
(w1.5 consultations per 1000 person-years). One in seven
patients with campylobacteriosis consulted their GP, resulting in
approximately one consultation per 1000 person-years based on
culture diagnostics. Other organisms occurred at rates of less
than one consultation per 1000 person-years. Salmonellosis was
uncommon (<0.2 consultations per 1000 person-years),
although one in three patients consulted their GP.
Only one case of CDAD occurred in the GP presentation
study, and no cases of L monocytogenes IID were identiﬁed.
Ratios to national surveillance
Table 2 presents, by organism, the rates of IID in the community
and presenting to GP, and the ratios of these rates to those
estimated from national surveillance data. Figures 4 and 5
illustrate reporting patterns for all IID and for the four major
pathogens, Campylobacter, Salmonella, norovirus and rotavirus. In
each diagram, the rates in the community, presenting to GP and
reported to national surveillance are represented as ellipses, with
the area of each ellipse proportional to the rate.
The ratios of community and GP presentation rates to
national surveillance rates were much higher for viruses than for
Figure 2 Recruitment in the general practice presentation study,
Infectious Intestinal Disease (IID) 2 Study, UK 2008e9.
72 Gut 2012;61:69e77. doi:10.1136/gut.2011.238386
Intestinal infectionsbacteria and protozoa. For every national surveillance case of
norovirus IID, there were 12.7 GP consultations (95% CI 8.8 to
18.3) and 288 community cases (95% CI 239 to 346). The
corresponding ratios for rotavirus were one in ﬁve (95% CI
3 to 7) and one in 43 (95% CI 30 to 62). By contrast, for every
national surveillance case of campylobacteriosis, there were
1.3 GP consultations (95% CI 0.9 to 1.8) and 9.3 community
cases (95% CI 6.0 to 14.4). For Salmonella, the corresponding
ratios were 1.4 GP consultations (95% CI 0.6 to 3.3) and
approximately ﬁve community cases (95% CI 1.2 to 18.2).
Among the protozoa, 2.3 GP consultations (95% CI 1.0 to 5.6)
and 8.2 (95% CI 2.1 to 31.7) community cases occurred for every
case of cryptosporidiosis reported to national surveillance. The
corresponding ﬁgures for giardiasis were somewhat higher,
although there was considerable uncertainty in the estimates.
Estimated annual cases and GP presentations
In 2009, there were approximately 16.9 million cases of IID and
over 1 million IID-related GP consultations. Campylobacter
accounted for over 500000 cases and approximately 80000 GP
consultations (table 3). Norovirus caused nearly three million
sporadic (non-outbreak-related) IID cases and approximately
130000 GP consultations. The burden from sapovirus was also
considerable, with an estimated 1.6 million sporadic cases and
nearly 100000 GP consultations, while rotavirus caused more
than 750000 cases and 80000 GP consultations.
Figure 3 Age-speciﬁc rates of
infectious intestinal disease general
practice (GP) consultationsdestimates
from the cohort and general practice
presentation studies, Infectious
Intestinal Disease 2 Study, UK 2008e9.
Table 1 Incidence rates of infectious intestinal disease in the community and presenting to general practice by organism, Infectious Intestinal
Disease 2 Study, UK 2008e9
Organism Test methods
Community Presenting to GP Ratio community/GP
Cases* PYy Ratez (95% CI) Cases* PYy Ratez (95% CI) RR (95% CI)
Bacteria
C perfringens A 7 4658.6 1.5 (0.5 to 3.9) 78 312232 0.24 (0.11 to 0.52) 6.0 (1.7 to 20.9)
Campylobacter spp. A 43 4658.6 9.3 (6 to 14.3) 400 312232 1.28 (0.90 to 1.82) 7.2 (4.1 to 12.7)
E 51 4658.6 10.9 (7.4 to 15.9) 693 312232 2.22 (1.65 to 2.97) 4.9 (3 to 7.9)
E coli O157 (VTEC) A 1 4658.6 0.3 (0 to 4.3) 4 312232 0.01 (0.00 to 0.09) 22.8 (0.9 to 610)
Enteroaggregative E coli D 28 4658.6 5.9 (3.4 to 10.2) 66 312232 0.21 (0.11 to 0.41) 28.4 (11.8 to 68.2)
Salmonella spp. A 3 4658.6 0.6 (0.2 to 2.4) 57 312232 0.18 (0.08 to 0.44) 3.4 (0.7 to 17.4)
E 3 4658.6 0.6 (0.2 to 2.4) 56 312232 0.18 (0.07 to 0.44) 3.5 (0.7 to 17.9)
Protozoa
Cryptosporidium B 3 4658.6 0.7 (0.2 to 2.7) 65 312232 0.20 (0.08 to 0.48) 3.5 (0.7 to 17.6)
C 6 4658.6 1.2 (0.4 to 3.9) 80 312232 0.25 (0.11 to 0.58) 4.9 (1.2 to 20.6)
Giardia B 4 4658.6 0.8 (0.2 to 3) 29 312232 0.09 (0.03 to 0.27) 9.3 (1.8 to 49.2)
C 9 4658.6 2.0 (0.7 to 5.6) 35 312232 0.11 (0.05 to 0.26) 18.2 (4.8 to 69.6)
Viruses
Adenovirusx C 48 4658.6 10.2 (6.8 to 15.4) 265 312232 0.84 (0.49 to 1.45) 12.1 (6.1 to 23.9)
Astrovirus D 25 4658.6 5.3 (3 to 9.4) 127 312232 0.40 (0.20 to 0.82) 13.1 (5.2 to 32.7)
Norovirus D 219 4658.6 47.0 (39.1 to 56.5) 648 312232 2.07 (1.44 to 2.99) 22.7 (15.1 to 34.2)
Rotavirusx C 59 4658.6 12.7 (8.7 to 18.4) 424 312232 1.36 (0.89 to 2.07) 9.4 (5.3 to 16.5)
Sapovirus D 121 4658.6 26.1 (20.1 to 33.8) 491 312232 1.57 (1.08 to 2.29) 16.6 (10.5 to 26.2)
*Mean number of cases from 20 imputations.
yPerson-years.
zCases per 1000 person-years.
xELISA for adenovirus and rotavirus was conducted in specimens from patients aged <5 years.
A, culture; B, enzyme immunoassay; C, ELISA and/or PCR; D, PCR; E, culture and/or PCR; GP, general practice; VTEC, verotoxin-producing E coli.
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Summary of main ﬁndings
This is one of the largest population-based studies of IID to date,
comprising over 4500 person-years of community follow-up and
over 300000 person-years of GP follow-up. Few researchers
12 23
have investigated the aetiology of IID in the general population
so comprehensively. We included a broad panel of organisms
using conventional and novel quantitative PCR diagnostics. The
greater sensitivity of PCR methods for viral diagnostics allows
much more reliable incidence estimates, particularly for noro-
virus and sapovirus. The results show Campylobacter is the major
bacterial IID agent, causing over half a million cases and 80000
GP consultations annually. Norovirus, commonly thought to
cause mild illness in institutional outbreaks, nevertheless
accounts for nearly 3 million sporadic cases annually and
130000 GP consultations.
To our knowledge, this is the ﬁrst study to report the high
population burden of sapovirus, which may partly be due to
emergence of a novel sapovirus strain during the study.
24 Low
population immunity levels may have facilitated its rapid
spread. Our estimates also provide a useful baseline for rotavirus
burden before the introduction of routine vaccination in the UK,
and indicate that C difﬁcile is a very uncommon cause of
diarrhoea in the community.
Comparison with other studies
In a previous study,
12 limited to England in the mid-1990s, using
the same case deﬁnition and similar methods, the reported IID
rates were 194 community cases and 33.1 GP consultations per
1000 person-years. In our study, the community incidence is
w40% higher, but GP consultation rates for all the major
pathogens have almost halved. This is consistent with data from
the Royal College of General Practitioners Weekly Returns
Service indicating a threefold decrease in IID-related consulta-
tions to its GP network between 1996 and 2008.
25 A major
change to primary care since the 1990s is the introduction of
telephone information and advice services. However, use of
services such as NHS Direct in England was low in our study
and cannot account for the decline in GP consultations. Instead,
increased self-management and perhaps a decrease in the
severity of illness from certain pathogens may be responsible.
Our case deﬁnition was more sensitive than those used in
other studies and may have resulted in milder illness being
captured. The effect of varying case deﬁnitions will be the
subject of more detailed investigation. The Dutch SENSOR
Study, which used a deﬁnition for IID of three or more loose
Table 2 Incidence rates of infectious intestinal disease (IID) in the community and presenting to general practice by organism, and ratios to national
surveillance, IID2 Study, UK 2008e2009
Organism
Community Presenting to general practice Reported to national surveillance
Rate* (95% CI) Rate* (95% CI) Rate* (95% CI)
Bacteria
C perfringens A 1.5 (0.5 to 3.9) 0.2 (0.1 to 0.5) 0.001 (0 to 0.001)
Reporting ratioy 2518.7 (890.7 to 7179.4) 419.1 (181.9 to 962.8) 1.0
Campylobacter A 9.3 (6 to 14.3) 1.3 (0.9 to 1.8) 0.997 (0.989 to 1.005)
Reporting ratioy 9.3 (6 to 14.4) 1.3 (0.9 to 1.8) 1.0
E coli O157 VTEC A 0.3 (0 to 4.3) 0.0 (0 to 0.1) 0.042 (0.04 to 0.043)
Reporting ratioy 7.4 (0.5 to 104.4) e 1.0
Salmonella A 0.6 (0.2 to 2.4) 0.2 (0.1 to 0.4) 0.133 (0.13 to 0.136)
Reporting ratioy 4.7 (1.2 to 18.2) 1.4 (0.6 to 3.3) 1.0
Protozoa
Cryptosporidium B 0.7 (0.2 to 2.7) 0.2 (0.1 to 0.5) 0.086 (0.084 to 0.089)
Reporting ratioy 8.2 (2.1 to 31.7) 2.3 (1 to 5.6) 1.0
Giardia B 0.8 (0.2 to 3) 0.1 (0 to 0.3) 0.061 (0.059 to 0.063)
Reporting ratioy 14.0 (4 to 49) 1.5 (0.5 to 4.5) 1.0
Viruses
Adenovirus C 10.2 (6.8 to 15.4) 0.8 (0.5 to 1.5) 0.055 (0.053 to 0.057)
Reporting ratioy 184.5 (122 to 279.3) 15.3 (8.8 to 26.3) 1.0
Astrovirus D 5.3 (3 to 9.4) 0.4 (0.2 to 0.8) 0.003 (0.003 to 0.003)
Reporting ratioy 1763.5 (970.1 to 3218.1) 135.1 (65.5 to 278.9) 1.0
Norovirus D 47.0 (39.1 to 56.5) 2.1 (1.4 to 3) 0.164 (0.011 to 0.02)
Reporting ratioy 287.6 (239.1 to 346) 12.7 (8.8 to 18.3) 1.0
Rotavirus C 12.7 (8.7 to 18.4) 1.4 (0.9 to 2.1) 0.296 (0.232 to 0.268)
Reporting ratioy 42.9 (29.5 to 62.4) 4.6 (3 to 7) 1.0
*Cases per 1000 person-years.
yThe reporting ratios represent the ratio of rates in the community and presenting to general practice relative to the rate of reports to national surveillance. Enteroaggregative E coli and
sapovirus are omitted from this table, as data on these organisms are not routinely collected at national level in all UK countries.
A, culture; B, enzyme immunoassay; C, ELISA and/or PCR; D, PCR; VTEC, verocytotoxin-producing E coli.
Figure 4 Patterns of reporting to national surveillance for all infectious
intestinal disease (IID), UK 2008e9. Black numbers represent the rates
(with 95% CIs) in the community, presenting to general practice and
reported to national surveillance. Red numbers represent the ratios of
incidence in the community and presenting to general practice
respective to the incidence of infectious intestinal disease reported to
national surveillance (with 95% CIs).
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Intestinal infectionsstools in a 24 h period,
23 produced a similar estimate (283 per
1000 person-years) to ours. Approximately 20% of patients in
our cohort experienced fewer than three loose stools in a 24 h
period, implying that, using comparable deﬁnitions, our study
would produce somewhat lower estimates of all-cause IID in the
community. Nevertheless, using comparable diagnostic
methods, rates in the community for Campylobacter, norovirus
and rotavirus were similar to those in both the previous IID
Study
12 26 and the Dutch SENSOR Study.
23 By contrast, the
incidence of salmonellosis in our study was considerably lower
than in those two studies. This reﬂects a decrease in contami-
nation of poultry products, particularly from Salmonella
Enteritidis phage type 4, following the introduction of vacci-
nation of breeder and layer ﬂocks in the mid-1990s.
27
We estimate that there are up to 17 million cases of sporadic
IID in the UK every year. Studies of IID burden in similar
settings using telephone survey methods generally produce
incidence estimates two to three times higher.
28 The reasons are
unclear, but may include differences in case deﬁnitions, tele-
scoping of symptoms among telephone survey respondents, and
reporting fatigue among cohort participants followed-up for
long periods.
28 In the IID2 Study, we conducted a parallel
Figure 5 Patterns of reporting to national surveillance for Campylobacter, Salmonella, norovirus and rotavirus, UK 2008e9. Black numbers represent
the rates per 1000 person-years (with 95% CIs) in the community, presenting to general practice and reported to national surveillance. Red numbers
represent the ratios of the incidence rates in the community and presenting to general practice compared with infectious intestinal disease reports to
national surveillance (with 95% CIs).
Table 3 Estimated annual numbers of infectious intestinal disease (IID) cases in the community and presenting to general practices by organism, IID2
Study, UK 2008e2009
Organism
Community Presenting to GP
Cases 95% CI Cases 95% CI
Bacteria
C perfringens A 89847 33565 to 240508 14983 6981 to 32157
Campylobacter spp. A 571949 369936 to 884276 78973 55486 to 112401
E coli O157 VTEC A 18916 1339 to 267201 824 120 to 5664
Enteroaggregative E coli D 365297 211351 to 631374 12893 6501 to 25567
Salmonella spp. A 38606 9968 to 149529 11291 4649 to 27418
Protozoa
Cryptosporidium B 43834 11393 to 168655 12488 5232 to 29805
Giardia B 52434 15022 to 183020 5617 1875 to 16822
Viruses
Adenovirus C 630251 417285 to 951906 52106 30219 to 89845
Astrovirus D 325642 182466 to 581165 24982 12260 to 50905
Norovirus D 2905278 2418208 to 3490451 128022 88784 to 184600
Rotavirus C 783737 539535 to 1138466 83850 54868 to 128141
Sapovirus D 1610041 1239580 to 2091219 97024 66661 to 141217
All IID 16935420 15680690 to 18277944 1096190 891659 to 1348301
A, culture; B, enzyme immunoassay; C, ELISA and/or PCR; D, PCR; VTEC, verocytotoxin-producing E coli.
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Intestinal infectionstelephone survey to study these differences in detail (to be
reported elsewhere).
IID-related GP consultation rates vary considerably by study:
the SENSOR study rate was half that estimated by us,
29 while
the rate recently reported in Germany was double.
30 These
differences are difﬁcult to interpret, but variations in primary
care provision and usage between countries may explain them.
Study limitations
Adherence to weekly follow-up in the cohort study was high.
Drop-outs accounted for losing <5% of total follow-up time.
Nevertheless, w10% of those invited were recruited into the
study. This is lower than previous studies in England (35%)
12
and the Netherlands (42%),
23 but similar to recent prospective,
population-based UK studies.
31 32 Study participants may differ
from the general population in terms of IID risk or propensity to
report symptoms. We standardised all rates to account for
differences in the age and sex structure between the cohort and
census populations, and we did not ﬁnd important differences in
IID rates by ethnicity, socioeconomic group, urbanerural resi-
dence or area-level deprivation (data not shown).
We based our estimates of community incidence on deﬁnite
IID cases. These could be conservative, since some cohort
participants reporting illness were classiﬁed as possible cases
because of missing symptom information. If deﬁnite and
possible cases were considered, the community rate nearly
doubled. We used deﬁnite cases only because information from
them on health service usage agrees with estimates from the GP
presentation study and NHS Direct, suggesting that these esti-
mates are more reliable than those based on all deﬁnite and
possible cases. In addition, our results show a marked decline in
community Salmonella incidence, but for Campylobacter, noro-
virus and rotavirus, for which control measures have not been
implemented, our estimates are similar to those reported
previously in England
12 26 and the Netherlands.
23
One in six patients presenting to GP with IID-compatible
symptoms was recruited into the GP presentation study, with
considerable variation by practice. Although we publicised the
study widely in participating practices, some GPs may not have
referred patients if they were too busy. To satisfy ethics
requirements, invited patients were given a 24 h cooling-off
period before providing consent. Some patients were unable or
unwilling to return for an interview on another day, and others
were no longer interested because their condition had improved.
We corrected for under-ascertainment using adjustment factors
to account for differences in ascertainment by age group, sex,
diagnostic category and practice.
In the cohort study, a third of cases did not provide a stool
specimen for microbiological examination, so we used multiple
imputation methods to infer missing organism information. Our
imputation models included variables most likely to predict the
likelihood of infection with different organisms, namely age
group and symptom proﬁle, but may not have dealt adequately
with missing data if other important factors related to positivity
with speciﬁc organisms had been omitted.
We used both conventional and quantitative PCR methods for
microbial diagnosis. PCR-based methods have greater sensitivity
for enteric viruses. For norovirus and rotavirus, however,
a substantial fraction of asymptomatic people have evidence of
infection using PCR.
33 We used previously validated PCR cut-off
values to distinguish clinically signiﬁcant from coincidental
infection with norovirus and rotavirus. Similar data do not exist
for other organisms, and we opted for a more sensitive
threshold. We may have overestimated incidence, particularly
for sapovirus, adenovirus and astrovirus, since, in some people,
infection may have been coincidental rather than causative.
Conversely, we may have underestimated Cryptosporidium and
Giardia rates; these organisms often cause illness lasting over
2 weeks, so cases of longer duration may have been excluded.
Despite extensive microbiological testing, w50% and 60% of
specimens tested in the GP presentation and cohort studies,
respectively, were negative for all the organisms investigated.
This is similar to previous studies
23 34 and may reﬂect the role of
other organisms for which we did not test, or hitherto unknown
pathogens. We excluded patients with known non-infectious
causes of IID, and required cases to be symptom-free for the
preceding 3 weeks and have illness lasting less than 2 weeks.
However, it is possible that a fraction of these stool-negative
cases had non-infectious causes such as transient irritable bowel
syndrome, either pre-existing or resulting from a prior episode of
IID.
The reporting ratios should be interpreted in their epidemio-
logical context. Norovirus cases in national statistics arise
primarily from institutional outbreaks, which were not included
in our study. We may therefore have overestimated the propor-
tion of sporadic cases in the community captured by national
surveillance. For organisms such as Campylobacter, which is
uncommonly associated with large outbreaks, the reporting
ratio reﬂects more accurately the ratio of community incidence
to national statistics.
Conclusions
The UK burden of IID is substantial, resulting in up to 17 million
sporadic cases annually. Despite this, IID-related GP consulta-
tions have declined substantially since the 1990s. Changes in
healthcare usage, rather than increased use of telephone infor-
mation and advice services, probably explain this. Tackling
Campylobacter is central to the Food Standards Agency’s strategy
andcrucialfor reducingfood-borneillnessburden.
35This involves
reducing contamination in poultry, a major source of human
infection,
36 and promoting safe food preparation to avoid cross-
contamination. By contrast, salmonellosis has declined dramati-
cally. C difﬁcile, very important in healthcare settings, appears to
be a rare cause of community IID, while enteric viruses account
fora large burdenofhealthcare useanddisease in thecommunity.
New rotavirus vaccines, if deemed cost-effective for routine
immunisation in theUK,showgreat promise for reducing burden
of rotavirus disease in children.
37 38 Our study provides
contemporaneous baseline estimates of rotavirus burden before
introduction of routine immunisation. For norovirus and sapo-
virus, organisms commonly regarded as mainly causing institu-
tional outbreaks, the large pool of community infection raises
important questions about control. Mitigating the impact of
these viruses includes scrupulous personal hygiene to avoid
person-to-person spread, and protecting shellﬁsh beds against
human sewage contamination to reduce food-related norovirus
infection. Understanding better the burden of disease that is
food-borne, and the relationship between virus circulation in the
community and transmission in institutional and healthcare
settings, is crucial for developing appropriate control strategies.
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